Physician profile
Xinye Wu
NPI 1427248103
$2,937.60
in general payments reported to CMS, 2019-2025
24 companies · $937 in 2025
The $937 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $104 · 2021: $491 · 2022: $681 · 2023: $329 · 2024: $169 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $576.50 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $408.74 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $209.76 | 2019-2022 | |
| Travere Therapeutics, INC. | $209.75 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $190.16 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $171.12 | 2020-2025 | Velphoro |
| Amgen INC. | $157.60 | 2022-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $144.67 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $138.74 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $128.02 | 2024-2025 | |
| Daiichi Sankyo INC. | $96.07 | 2020-2021 | |
| Madrigal Pharmaceuticals | $83.82 | 2025 | Rezdiffra |
| Ardelyx, INC. | $83.66 | 2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $63.26 | 2022-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $55.24 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.76 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.55 | 2025 | Jardiance |
| Kyowa Kirin, INC. | $32.93 | 2023-2025 | Crysvita |
| Vifor Pharma, INC. | $30.50 | 2022-2023 | Veltassa |
| Scpharmaceuticals INC. | $24.03 | 2025 | |
| Horizon Therapeutics Plc | $16.77 | 2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Renalytix Ai, INC. | $15.48 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Glaxosmithkline, LLC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xinye Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.